CEVEC Signs License Agreement with Yuhan of South Korea
News Dec 21, 2012
CEVEC Pharmaceuticals and Yuhan Corporation have announced the signing of a CAP-Technology license agreement.
The license will enable Yuhan to utilize CEVEC’s CAP-T™ and CAP® cell expression systems for the production and development of various therapeutic proteins.
CAP-T™ CAP® cells are immortalized cell lines for transient and stable protein production developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns.
The Technology allows for superior protein yields in a shorter time frame than traditional methods.
“With Yuhan Corporation we have won one of the most prestigious Asian Pharma Companies as a customer. We’re very pleased that Yuhan has chosen our CAP and CAP-T expression systems as a pivotal platform to develop therapeutically relevant molecules. I’m convinced that the cells will have a major impact to develop more efficient biologics and will also shorten the timeline to enter clinical phases” stated Wolfgang Kintzel, CEO at CEVEC.
Dr. Jong-Gyun Kim, Head of the Bio-Innovation Unit at Yuhan Research Institute said: “After evaluating CAP and CAP-T we are excited about the potential of CEVEC’s CAP Technology. We obtained outstanding results from transfections of various target proteins in CAP-cells and we are convinced that this expression system with it’s authentic human glycosylation profile will be of great benefit to further develop our pipeline molecules."
Decoding the 3-D Structure of HuntingtinNews
Mutations on a single gene, the huntingtin gene, are the cause of Huntington's disease. They lead to an incorrect form of the correspondent protein. With the help of cryo-electron microscopy, researchers have now decoded the three-dimensional, molecular structure of the healthy human huntingtin protein.READ MORE